Drugs / RP-L401
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04525352 | Nov 2020 → May 2021 | autosomal recessive osteopetrosis | Rocket Pharmaceuticals Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RP-L401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04525352 ↗ |
| Target | TCIRG1 | “lentiviral vector carrying the TCIRG1 transgene” NCT04525352 ↗ |